Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, and offers Senza II and Senza Omnia SCS systems. It also offers Senza HFX iQ platform that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, and HFX App, a patient remote control and the wireless trialing system. The company also provides HFX AdaptivAI, a pain management platform that powers the HFX iQ SCS system, and surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was formerly known as NBI Development, Inc. and changed its name to Nevro Corp. in June 2007. The company was incorporated in 2006 and is based in Redwood City, California. As of April 3, 2025, Nevro Corp. operates as a subsidiary of Globus Medical, Inc.
Market Headwinds | Nevro faces declining sales and market share in the spinal cord stimulation sector, with challenges expected to persist through 2025 |
Strategic Pivot | Explore Nevro's product launches and acquisitions, including HFX AdaptivAI and Vyrsa SI joint therapy, aimed at diversifying revenue streams |
Financial Outlook | Analysts project 2025 sales of $425 million, with price targets ranging from $4 to $7, reflecting cautious sentiment amid market uncertainties |
Value Proposition | Delve into Nevro's strategic review process and strong cash position, which could unlock shareholder value despite current market challenges |